Literature DB >> 10475063

The coactivators p300 and CBP have different functions during the differentiation of F9 cells.

H Ugai1, K Uchida, H Kawasaki, K K Yokoyama.   

Abstract

We have characterized an element (differentiation response element, DRE) in the promoter region of the c-jun gene that is both necessary and sufficient for retinoic acid (RA) and adenovirus early region (E1A) mediated up-regulation of c-jun gene expression during the differentiation of F9 cells. The DRF complex, which binds specifically to DRE, is composed of the E1A-associated protein p300 and the activation transcription factor-2 (ATF-2) as a DNA-binding subunit of the DRF. The molecular association of p300 and ATF-2 enhances the transcription of the c-jun gene, which requires protein kinase C alpha mediated phosphorylation of Ser-121 of ATF-2 within its p300 interaction domain. We used antisense oligodeoxynucleotides (AS-ODNs) capable of binding specifically to the mRNA for either p300 or CBP to examine the individual roles of p300 and CBP during the RA-induced differentiation, exit from the cell cycle, and apoptosis of F9 cells. F9 cells treated with AS-ODNs specific for p300 mRNA became resistant to RA-induced differentiation, while cells incubated with AS-ODNs specific for CBP mRNA were still able to differentiate. Despite their similarities p300 and CBP appear to have distinct functions during the differentiation of F9 cells. These results suggest that ATF-2 and p300 cooperate in the control of transcription by forming a protein complex in response to RA or E1A, and that the phosphorylation of ATF-2 and p300 is probably a signaling event in the pathway that leads to the transactivation of the c-jun gene in F9 cell differentiation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10475063     DOI: 10.1007/s001099900021

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  8 in total

1.  p300 is involved in formation of the TBP-TFIIA-containing basal transcription complex, TAC.

Authors:  Dimitra J Mitsiou; Hendrik G Stunnenberg
Journal:  EMBO J       Date:  2003-09-01       Impact factor: 11.598

2.  Genetic heterogeneity in Rubinstein-Taybi syndrome: mutations in both the CBP and EP300 genes cause disease.

Authors:  Jeroen H Roelfsema; Stefan J White; Yavuz Ariyürek; Deborah Bartholdi; Dunja Niedrist; Francesco Papadia; Carlos A Bacino; Johan T den Dunnen; Gert-Jan B van Ommen; Martijn H Breuning; Raoul C Hennekam; Dorien J M Peters
Journal:  Am J Hum Genet       Date:  2005-02-10       Impact factor: 11.025

3.  Quantitative analysis of CBP- and P300-induced histone acetylations in vivo using native chromatin.

Authors:  Kirk J McManus; Michael J Hendzel
Journal:  Mol Cell Biol       Date:  2003-11       Impact factor: 4.272

4.  Mammalian Rcd1 is a novel transcriptional cofactor that mediates retinoic acid-induced cell differentiation.

Authors:  Noriko Hiroi; Takaaki Ito; Hanako Yamamoto; Takahiro Ochiya; Shigeki Jinno; Hiroto Okayama
Journal:  EMBO J       Date:  2002-10-01       Impact factor: 11.598

5.  Molecular interaction and synergistic activation of a promoter by Six, Eya, and Dach proteins mediated through CREB binding protein.

Authors:  Keiko Ikeda; Yoko Watanabe; Hiromi Ohto; Kiyoshi Kawakami
Journal:  Mol Cell Biol       Date:  2002-10       Impact factor: 4.272

6.  CREB-binding protein is a mediator of neuroblastoma cell death induced by the histone deacetylase inhibitor trichostatin A.

Authors:  Chitra Subramanian; Jason A Jarzembowski; Anthony W Opipari; Valerie P Castle; Roland P S Kwok
Journal:  Neoplasia       Date:  2007-06       Impact factor: 5.715

7.  Altering cancer transcriptomes using epigenomic inhibitors.

Authors:  Malaina Gaddis; Diana Gerrard; Seth Frietze; Peggy J Farnham
Journal:  Epigenetics Chromatin       Date:  2015-02-24       Impact factor: 4.954

8.  Spatiotemporal expression of histone acetyltransferases, p300 and CBP, in developing embryonic hearts.

Authors:  Guozhen Chen; Jing Zhu; Tiewei Lv; Gang Wu; Huichao Sun; Xupei Huang; Jie Tian
Journal:  J Biomed Sci       Date:  2009-02-23       Impact factor: 8.410

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.